Phaseline

Targets › MTNR1A

MTNR1A (Melatonin receptor type 1A): drug programs, companies and trials

30 programs from 30 companies in 34 trials: 14 Phase 2, 11 Phase 3, 8 Phase 4, 1 Phase 1; Psychiatry, Other, Neurology; next expected readout Nov 2026.

High affinity receptor for melatonin. Likely to mediate the reproductive and circadian actions of melatonin. (UniProt, P48039)

Open in Phaseline: the race on MTNR1A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of Oklahomamelatonin
Melatonin receptor agonist
MTNR1A, MTNR1BPhase 4HealthyNov 2026
Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of HealthMelatonin
Melatonin receptor agonist
MTNR1A, MTNR1BPhase 4Ischemic Stroke, AcuteDec 2026
Mahidol UniversityMelatonin
Melatonin receptor agonist
MTNR1A, MTNR1BPhase 4IBD (Inflammatory Bowel Disease)Apr 2027
University Hospital, Basel, SwitzerlandMelatonin
Melatonin receptor agonist
MTNR1A, MTNR1BPhase 4Hypoactive DeliriumDec 2027
Instituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranMelatonin
Melatonin receptor agonist
MTNR1A, MTNR1BPhase 4Obstructive Sleep Apnea of AdultDec 2027
Massachusetts General HospitalMelatonin
Melatonin receptor agonist
MTNR1A, MTNR1BPhase 4DepressionJul 2028
Thammasat UniversityMelatonin
Melatonin receptor agonist
MTNR1A, MTNR1BPhase 4Melasma–
Al-Azhar UniversityMelatonin
Melatonin receptor agonist
MTNR1A, MTNR1BPhase 4Cataract Surgery Anesthesia–
Bart KoesMelatonin
Melatonin receptor agonist
MTNR1A, MTNR1BPhase 3Chronic Low-back Pain (cLBP)Dec 2026
Arash AfshariMelatonin
Melatonin receptor agonist
MTNR1A, MTNR1BPhase 3Emergence DeliriumMar 2027
Monash UniversityMelatonin
Melatonin receptor agonist
MTNR1A, MTNR1BPhase 3Fetal Growth RetardationApr 2027
Rutgers, The State University of New JerseyMelatonin
Melatonin receptor agonist
MTNR1A, MTNR1BPhase 3Acute Kidney InjuryJun 2027
Emory UniversityMelatonin
Melatonin receptor agonist
MTNR1A, MTNR1BPhase 3Orthopedic TraumaJul 2027
Vanda PharmaceuticalsTasimelteon
Melatonin receptor agonist
MTNR1A, MTNR1BPhase 3Sleep Wake Disorders; Insomnia DisorderNov 2027
Assistance Publique - Hôpitaux de ParisMelatonin
Melatonin receptor agonist
MTNR1A, MTNR1BPhase 3Major Depressive Disorder (MDD) With InsomniaAug 2028
Gustav StalhammarMelatonin
Melatonin receptor agonist
MTNR1A, MTNR1BPhase 3Uveal MelanomaJan 2031
Tanta UniversityMelatonin
Melatonin receptor agonist
MTNR1A, MTNR1BPhase 3Cardiomyopathies–
Ain Shams UniversityMelatonin
Melatonin receptor agonist
MTNR1A, MTNR1BPhase 2Comparative Effectiveness; Diabetic Peripheral NeuropathyDec 2026
Leslie SwansonMelatonin
Melatonin receptor agonist
MTNR1A, MTNR1BPhase 2Bipolar DisorderDec 2026
Ciusss de L'Est de l'Île de MontréalMelatonin
Melatonin receptor agonist
MTNR1A, MTNR1BPhase 2DeliriumDec 2026
M.D. Anderson Cancer CenterMelatonin
Melatonin receptor agonist
MTNR1A, MTNR1BPhase 2Sleep; Hematopoietic and Lymphoid Cell NeoplasmFeb 2027
Beni-Suef UniversityMelatonin
Melatonin receptor agonist
MTNR1A, MTNR1BPhase 2Ureteral Stent-Related SymptomsApr 2027
University Hospital, Strasbourg, FranceMelatonin
Melatonin receptor agonist
MTNR1A, MTNR1BPhase 2Idiopathic HypersomniaSep 2027
Lars Vedel KessingMelatonin
Melatonin receptor agonist
MTNR1A, MTNR1BPhase 2Bipolar Affective DisorderJun 2028
Lone BaandrupMelatonin
Melatonin receptor agonist
MTNR1A, MTNR1BPhase 2Psychiatric DisordersFeb 2029
University of Illinois ChicagoMelatonin
Melatonin receptor agonist
MTNR1A, MTNR1BPhase 2Diabetes Mellitus–
University of Child Health Sciences and Children's Hospital, LahoreMelatonin
Melatonin receptor agonist
MTNR1A, MTNR1BPhase 2Hypoxic Ischaemic Encephalopathy (HIE)–
Benha UniversityMelatonin
Melatonin receptor agonist
MTNR1A, MTNR1BPhase 2ICS–
Sultan Qaboos UniversityMelatonin
Melatonin receptor agonist
MTNR1A, MTNR1BPhase 2Delirium–
Mian Muhammad Hassan AhmedMelatonin
Melatonin receptor agonist
MTNR1A, MTNR1BPhase 1Pneumonia Childhood–

Conditions

Sleep Wake Disorders (2) Delirium (2) Insomnia Disorder (1) Chronic Low-back Pain (cLBP) (1) Major Depressive Disorder (MDD) With Insomnia (1) Diabetes Mellitus (1) Depression (1) Hypoxic Ischaemic Encephalopathy (HIE) (1) ICS (1) Ureteral Stent-Related Symptoms (1) Sleep (1) Hematopoietic and Lymphoid Cell Neoplasm (1)

Modalities

small molecule (26)

Companies

Vanda Pharmaceuticals (1) Bart Koes (1) Assistance Publique - Hôpitaux de Paris (1) Ciusss de L'Est de l'Île de Montréal (1) University of Illinois Chicago (1) Massachusetts General Hospital (1) University of Child Health Sciences and Children's Hospital, Lahore (1) Benha University (1) Beni-Suef University (1) M.D. Anderson Cancer Center (1) Mahidol University (1) Thammasat University (1) Mian Muhammad Hassan Ahmed (1) Monash University (1) Lars Vedel Kessing (1) Ain Shams University (1) Rutgers, The State University of New Jersey (1) Leslie Swanson (1) Al-Azhar University (1) University of Oklahoma (1)

Related targets

MTNR1B (30)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.